Skip to main content

Table 4 Relationship between clinical factors and OS in GC patients treated with S-1 adjuvant chemotherapy

From: An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer

Factors N = 100 Univariate analysis Multivariate analysis
P-valuea HR (95% CI)b P-valueb
Sex (M/F) 73/27 0.417   
Age (< 65/≥65 years) 41/59 0.558   
Tumor size (< 60/≥60 mm) 48/52 0.008* 3.115 (1.230–7.889) 0.017
Histologic type (Diff/Undiff) 35/65 0.005* 4.472 (1.308–15.287) 0.017
pT (1/2/3/4) 5/12/41/42 0.366   
pN (0/1/2/3) 14/25/31/30 0.023   
pStage (II/III) 39/61 0.043   
pNLR (+/−) 50/50 0.018   
pPLR (+/−) 50/50 0.074   
iNLR (+/−) 26/74 0.455   
iPLR (+/−) 50/50 0.308   
fNLR (+/−) 38/62 < 0.001* 6.736 (2.420–18.748) < 0.001
fPLR (+/−) 35/65 0.004*   
CEA (< 5.0/≥5.0 ng/ml) 26/74 0.118   
CA19–9 (< 37.0/≥37.0 U/ml) 18/82 0.262   
  1. M, male; F, female; Diff, differentiated type; Undiff, undifferentiated type; pT, pN, pStage = pathological T stage, N stage. Pathological cancer stage according to the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual; pNLR or pPLR, preoperative neutrophil or platelet-to-lymphocyte ratio; iNLR and iPLR, the ratio of the NLR or PLR on the initial day of adjuvant chemotherapy to the pNLR or pPLR; fNLR and fPLR, the ratio of the NLR or PLR on the final day of adjuvant chemotherapy to the iNLR or iPLR; CEA, carcinoembryonic antigen; CA19–9, carbohydrate antigen 19–9; aLog-rank test; bCox proportional hazards model; *P-value indicates statistical significance after false discovery rate correction
\